Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia

[1]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[2]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[3]  Apolipoprotein ε4-Allele as a Significant Risk Factor for Conversion from Mild Cognitive Impairment to Alzheimer’s disease: a Meta-analysis of Prospective Studies , 2013, Journal of Molecular Neuroscience.

[4]  M. Pontecorvo,et al.  Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  V. Fonov,et al.  Brain amyloid deposition and metabolism in early and late mild cognitive impairment , 2012, Alzheimer's & Dementia.

[6]  V. Fonov,et al.  Brain beta-amyloid deposition and metabolism in early and late mild cognitive impairment , 2012, Alzheimer's & Dementia.

[7]  S. Melquist,et al.  Changes in core biomarkers in cerebrospinal fluid and cognitive ability in patients with Alzheimer's disease: A two-year longitudinal study , 2012, Alzheimer's & Dementia.

[8]  C. Jack,et al.  Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance , 2012, Neurobiology of Aging.

[9]  Clifford R Jack,et al.  Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. , 2012, Archives of neurology.

[10]  D. Brooks,et al.  The prognostic value of amyloid imaging , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Frederik Barkhof,et al.  Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  T. Goldberg,et al.  Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. , 2011, Archives of general psychiatry.

[13]  Jesse S. Jin,et al.  Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate Predictors , 2011, PloS one.

[14]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[15]  Jacob Grand,et al.  Clinical features and multidisciplinary approaches to dementia care , 2011, Journal of multidisciplinary healthcare.

[16]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[17]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[18]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[19]  Nick C. Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup , 2011 .

[20]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[21]  G. Frisoni,et al.  The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment , 2010, Alzheimer's & Dementia.

[22]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[23]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[24]  A. Dale,et al.  Subregional neuroanatomical change as a biomarker for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[25]  M. Sarazin,et al.  Faculty Opinions recommendation of Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. , 2009 .

[26]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[27]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[28]  Jeffrey A. James,et al.  Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.

[29]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[30]  Y. Yuan,et al.  Fluorodeoxyglucose–Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis , 2008, American Journal of Neuroradiology.

[31]  K. Blennow,et al.  Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[32]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[33]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[34]  C. Jack,et al.  3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. , 2007, Brain : a journal of neurology.

[35]  Simon A. Moss,et al.  b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease , 2007 .

[36]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[37]  A. Drzezga,et al.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[39]  Miia Kivipelto,et al.  Introduction: Mild cognitive impairment: beyond controversies, towards a consensus , 2004 .

[40]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[41]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[42]  C. Monaghan,et al.  Dementia diagnosis and disclosure: a dilemma in practice. , 2004, Journal of clinical nursing.

[43]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[44]  G. Pinner.  Truth-telling and the diagnosis of dementia , 2000, British Journal of Psychiatry.

[45]  A. Smith,et al.  The experience of research participation and the value of diagnosis in dementia : Implications for practice , 1998 .

[46]  D. Coakley,et al.  Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis , 1996, BMJ.